Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

CVM vs AGEN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

AGEN Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 7–3 Matrix Metrics)

AGEN Overall Winner 6-Pillar Tally: CVM 0 – 5 AGEN (1 Tie) Matrix Metrics: CVM 3 – 7 AGEN

As of Nov 16, 2026, Agenus Inc. (AGEN) is the stronger overall head-to-head candidate over Cel-Sci Corporation (CVM) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CVM carries a Unified Composite Score of 56.6/100 (HOLD) at $1.59 (23.0x Forward P/E, 0.0% operating margin), whereas AGEN carries 51.5/100 (HOLD) at $6.34 (3.7x Forward P/E, 38.9% operating margin).

  • Composite vs. Pillar Nuance: While CVM currently prints a higher short-term Unified Composite Score (56.6/100 HOLD vs. AGEN 51.5/100 HOLD), AGEN captures the overall institutional head-to-head verdict (7–3 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (38.9% vs. 0.0% operating margin) and revenue trajectory (+4.1% vs. -62.7% YoY).
  • Technical & Structure Timing Caution: CVM is currently in a Breakdown options structure phase (RSI 57.1); meanwhile AGEN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 43.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CVM vs AGEN
CVM NYSE American
Cel-Sci Corporation
Biological Products, (No Disgnostic Substances)
$1.59
+24.22% 1D
Market Cap $20.9M
TTM Revenue $28,558
Forward P/E 23.0x
Beta / 30D Vol 0.65β · 120% Vol
Unified Composite Score
56.6 / 100 HOLD
Tech 60.0 Fund 54.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 57
RSI-14: 57.1 · SMA20: $1.46 · SMA50: $1.66
AGEN NASDAQ Head-to-Head Winner
Agenus Inc.
Biological Products, (No Disgnostic Substances)
$6.34
-5.79% 1D
Market Cap $310.8M
TTM Revenue $34M
Forward P/E 3.7x
Beta / 30D Vol 1.60β · 76% Vol
Unified Composite Score
51.5 / 100 HOLD
Tech 49.0 Fund 55.0 Flow 66.0 Mom 50.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -4.9%), weak momentum, RSI 44
RSI-14: 43.8 · SMA20: $6.74 · SMA50: $7.33

6-Pillar Scorecard Institutional Category Breakdown (CVM 0 – 5 AGEN)

Columns: Metric · CVM · AGEN
1. Valuation Multiples AGEN
Forward P/E 23.0x 3.7x
Trailing P/E 23.0x 29.9x
PEG Ratio 1.12x 1.44x
EV / Revenue N/M 8.9x
2. Growth & Scale AGEN
Revenue Growth (YoY) -62.7% +4.1%
Earnings Growth (YoY) +0.0% -99.0%
TTM Revenue (USD) $28,558 $34M
Market Cap $20.9M $310.8M
3. Profitability & Quality AGEN
Gross Margin N/A N/A
Operating Margin 0.0% 38.9%
Net Profit Margin 0.0% 30.8%
Return on Equity (ROE) -252.5% -1278.8%
4. Balance Sheet & Cash Flow AGEN
Cash Generation (TTM) -$17M -$35M
Cash Flow Margin N/A -103.7%
Net Cash / Leverage $6.6M Net Debt (1.24x D/E) $9.3M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning AGEN
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile N/A (N/A) 95.2% (11th %ile)
Put/Call OI Skew N/A 0.02x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning High-Margin Pricing Power Moat
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CVM (3) vs AGEN (7)
Institutional Metric CVM AGEN Criterion Row Edge
Market Capitalization
Scale
$20.9M $310.8M Larger Scale AGEN
Trailing P/E Ratio
Valuation
23.0x 29.9x Lower Multiple CVM
Forward P/E Ratio
Valuation
23.0x 3.7x Lower Multiple AGEN
Revenue Growth (YoY)
Growth
-62.7% +4.1% Higher Growth AGEN
Operating Margin (TTM)
Profitability
0.0% 38.9% Higher Margin AGEN
Net Profit Margin
Profitability
0.0% 30.8% Higher Margin AGEN
Return on Equity (ROE)
Capital Efficiency
-252.5% -1278.8% Higher ROE CVM
52-Week Range Position
Momentum
10% ($1–$8) 48% ($3–$10) Stronger Trend AGEN
Beta / 30D Volatility
Risk Regime
0.65β · 120% Vol 1.60β · 76% Vol Lower Realized Risk AGEN
Unified Institutional Score
Composite Signal
56.6 / 100 (HOLD) 51.5 / 100 (HOLD) Higher Composite CVM
Trailing 12M Revenue (USD)
Operating Scale
$28,558 $34M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.12x PEG · N/M EV/Rev 1.44x PEG · 8.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$17M ($6.6M Net Debt (1.24x D/E)) -$35M ($9.3M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon AGEN +16.14 pp
CVM: -11.17% · AGEN: +4.97%
3M Horizon CVM +15.8 pp
CVM: +0.0% · AGEN: -15.8%
6M Horizon AGEN +108.19 pp
CVM: -7.56% · AGEN: +100.63%
1Y Horizon AGEN +122.06 pp
CVM: -75.98% · AGEN: +46.08%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period CVM Revenue AGEN Revenue CVM Op. Margin AGEN Op. Margin Margin Leader
FY2018 N/A $40M N/A -336.6% AGEN
FY2019 N/A $150M N/A -46.7% AGEN
FY2020 N/A $90M N/A -133.0% AGEN
FY2021 N/A $300M N/A 8.7% AGEN
FY2022 N/A $100M N/A -183.0% AGEN
FY2023 N/A $160M N/A -102.1% AGEN
FY2024 N/A $100M N/A -116.4% AGEN
FY2025 N/A $110M N/A -17.7% AGEN

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CVM BREAKDOWN
29d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CVM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
AGEN BREAKDOWN
33d in phase · OBV NEUTRAL
Current IV 95.2%
IV Percentile 11th %ile
Put/Call OI Skew 0.02x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact AGEN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CVM Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $20.9M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
AGEN Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $310.8M market capitalization and 38.9% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CVM vs AGEN Key Questions & Quantitative Answers

As of Nov 16, 2026, Agenus Inc. (AGEN) is the stronger overall head-to-head candidate over Cel-Sci Corporation (CVM) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CVM carries a Unified Composite Score of 56.6/100 (HOLD) at $1.59 (23.0x Forward P/E, 0.0% operating margin), whereas AGEN carries 51.5/100 (HOLD) at $6.34 (3.7x Forward P/E, 38.9% operating margin). Composite vs. Pillar Nuance: While CVM currently prints a higher short-term Unified Composite Score (56.6/100 HOLD vs. AGEN 51.5/100 HOLD), AGEN captures the overall institutional head-to-head verdict (7–3 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (38.9% vs. 0.0% operating margin) and revenue trajectory (+4.1% vs. -62.7% YoY). Technical & Structure Timing Caution: CVM is currently in a Breakdown options structure phase (RSI 57.1); meanwhile AGEN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 43.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

AGEN leads the Growth & Scale pillar: CVM posts -62.7% YoY revenue growth and +0.0% YoY earnings growth on $28,558 TTM revenue (N/A gross margin, 0.0% operating margin), compared with AGEN at +4.1% YoY revenue growth and -99.0% YoY earnings growth on $34M TTM revenue (N/A gross margin, 38.9% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), CVM cumulative revenue shifted N/A while AGEN shifted +175.0%. In operating R&D and SG&A reinvestment, CVM deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for AGEN.

AGEN screens cheaper on headline valuation multiples. CVM trades at 23.0x Forward P/E, 23.0x Trailing P/E, 1.12x PEG, and N/M EV/Revenue (unreported FCF margin), whereas AGEN trades at 3.7x Forward P/E, 29.9x Trailing P/E, 1.44x PEG, and 8.9x EV/Revenue (-103.7% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CVM (-252.5% ROE) versus AGEN (-1278.8% ROE) capital efficiency.

In options market volatility and institutional positioning, CVM carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (0.65β · 120% Vol realized risk). By comparison, AGEN carries 95.2% implied volatility (11th %ile, Compressed (<25th %ile)), a 0.02x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.60β · 76% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.